|
:crazy: .... okay... I'm a dingbat....
.... but..... so.... what is Sanofi's gain then? At the time they were trying to compete against Mylan they were charging the same and insurance companies would cover the Auvi-q. And, had a failed product that had to be pulled from the market. So, inherently they were charging the same for defective products.